Single-Cell Omics Market Report 2026

The single-cell omics market size has grown rapidly in recent years. It will grow from $2.39 billion in 2025 to $2.78 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to advancements in next-generation sequencing, increasing academic research funding, growing cancer research initiatives, demand for cellular heterogeneity analysis, improvements in cell isolation technologies.

The single-cell omics market size is expected to see rapid growth in the next few years. It will grow to $5.27 billion in 2030 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to expansion of precision medicine programs, integration of AI in omics analysis, increasing pharmaceutical R&D investments, rising adoption in clinical diagnostics, development of cost-effective single-cell platforms. Major trends in the forecast period include rising adoption of multi-omics approaches, growing demand for high-resolution cellular analysis, expansion of single-cell applications in oncology research, increased use of microfluidics for cell isolation, standardization of single-cell analysis workflows.

The rising prevalence of cancer is expected to support the growth of the single-cell omics market in the years ahead. Cancer includes a broad range of diseases that can originate in nearly any organ or tissue when abnormal cells multiply uncontrollably, cross normal boundaries, and spread to distant organs or infiltrate surrounding tissues. Single-cell omics data is widely applied to identify biomarkers for cancer detection, forecast disease outcomes, and discover new therapeutic targets within defined clinical populations. For example, in May 2024, according to the National Institutes of Health, a US-based government agency, approximately 18.1 million individuals in the United States were living as cancer survivors as of January 2022, and this number is projected to increase to 22.5 million by 2032. Consequently, the increasing cancer burden is driving the expansion of the single-cell omics market.

Key companies operating in the single-cell omics market are focusing on the development of advanced kits, including sequencing kits, to support single-cell research applications and enhance revenue generation. Sequencing kits are bundled sets of reagents and materials designed to simplify and optimize genetic sequencing workflows in laboratory settings. For instance, in February 2023, Singular Genomics Systems, Inc., a US-based company focused on next-generation sequencing technologies, launched Max Read Kits for single-cell sequencing on its G4 Sequencing Platform. These kits are compatible with commonly used 10x Genomics assays and allow sequencing of 4 to 16 samples in a single run. The Max Read Kits provide up to 800 million reads per flow cell with Q30 quality levels between 80% and 90%. Additionally, Singular Genomics enhanced the performance parameters of the G4 Sequencing Platform’s F2 and F3 flow cells, enabling up to 1.8 billion reads per run on F3 flow cells for specific applications.

In August 2025, 10x Genomics, a US-based provider of single-cell and spatial biology instruments, consumables, and software, acquired Scale Biosciences for $13.5 million. Through this acquisition, 10x Genomics aims to strengthen its Chromium platform by integrating Scale’s scalable single-cell technologies, thereby advancing high-throughput single-cell analysis while improving affordability and accessibility. Scale Biosciences is a US-based company specializing in the development and delivery of single-cell omics solutions.

Major companies operating in the single-cell omics market are Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Thermo Fisher Scientific Inc, Agilent Technologies Inc, Sartorius AG, Illumina Inc, Bio Rad Laboratories Inc, Qiagen NV, Tecan Group Ltd, BGI Genomics Co Ltd, 10x Genomics Inc, Takara Bio Inc, NanoString Technologies Inc, Vizgen, Deepcell, Mission Bio Inc, Standard BioTools Inc, CYTENA GmbH, Single Cell Discoveries.

North America was the largest region in the single-cell omics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-cell omics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single-cell omics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created moderate challenges for the single-cell omics market by increasing costs of imported sequencing instruments, reagents, microfluidic chips, and analytical equipment, impacting overall research budgets and slowing procurement cycles. The effects are most pronounced across single-cell genomics and transcriptomics segments, particularly in regions such as Asia-Pacific and Europe that rely heavily on cross-border trade for advanced laboratory technologies. Academic research organizations and biotechnology firms face higher operational costs, while some suppliers are responding by localizing manufacturing and supply chains. In the long term, tariffs may support regional production capabilities and encourage domestic innovation in single-cell technologies.

The single-cell omics market research report is one of a series of new reports that provides single-cell omics market statistics, including single-cell omics industry global market size, regional shares, competitors with a single-cell omics market share, detailed single-cell omics market segments, market trends and opportunities, and any further data you may need to thrive in the single-cell omics industry. This single-cell omics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Single-cell omics involves profiling individual cells obtained from heterogeneous cell populations at different cellular stages, enabling detailed analysis of normal development and disease mechanisms at the single-cell level. These approaches are applied to study cellular heterogeneity, identify distinct cell types, investigate diseases, and support therapeutic development.

The key types of single-cell omics products include single-cell genomics, single-cell transcriptomics, single-cell proteomics, and single-cell metabolomics. Single-cell genomics is an advanced method for classifying individual cells, allowing the detection of rare cell types and the characterization of unique cellular features. The technologies used include cell isolation methods, sample preparation techniques, and next-generation sequencing analysis, which are applied across oncology, cell biology, neurology, and immunology. The primary end users include pharmaceutical and biotechnology companies, academic and research institutions, hospital and diagnostic laboratories, and others.

The single-cell omics market includes revenues earned by entities through single-cell sorting and isolation, single-cell sample preparation kits, and related single-cell data analysis software. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.